Please wait while the formulary information is being retrieved.
HEMGENIX (etranacogene dezaparvovec-drlb)
- bleeding in hemophilia B
- blood clotting disorder from factor IX
1x10exp13 gc/mL intravenous suspension
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Pregnancy
Severe
Moderate
- Abnormal hepatic function tests
HEMGENIX (etranacogene dezaparvovec-drlb)
- bleeding in hemophilia B
- blood clotting disorder from factor IX
- Increased alanine transaminase
- Increased aspartate transaminase
- Fatigue
- Flu-like symptoms
- Headache disorder
- Increased creatine kinase level
More Frequent
Severe
Less Severe
- Hypersensitivity drug reaction
- Malaise
- Nausea
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
etranacogene dezaparvovec
Safety and efficacy not established in pediatrics.
- 1 Day – 18 Years
- Safety and efficacy not established in pediatrics.
Etranacogene Dezaparvovec-drlb
- Severity Level:
D
- Additional Notes: Insuff human data; per drug manuf, tx not indicated in women
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Etranacogene Dezaparvovec-drlb
Per drug manuf, not indicated in women
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Per drug manuf, not indicated in women |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Bleeding episode in hemophilia B | |
| D67 | Hereditary factor IX deficiency |
| Hemophilia B | |
| D67 | Hereditary factor IX deficiency |
| 0-9 | A-Z |
|---|---|
| D67 | Hereditary factor IX deficiency |
| D67 | Hereditary factor IX deficiency |
Formulary Reference Tool